{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-106699","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2026-09-10T20:01:38+00:00","discovered_at":"2026-09-10T20:04:06.778556+00:00","generated_at":"2026-09-10T20:04:20.752890+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Yarrow Bioscience advances YB-101: FDA Fast Track, Phase 2a/2b trial started","bullets":["In-licensed YB-101 (anti-TSHR antibody) from GenSci in Dec 2025 for Graves' disease and thyroid eye disease outside China.","FDA cleared IND for GD in March 2026; Fast Track designation granted May 20, 2026.","Initiated combined Phase 2a/2b trial in June 2026; Phase 2a data expected H2 2027.","Merger with Yarrow Bioscience Operating Company Corp. (formerly Yarrow Bioscience, Inc.) reflected in business update."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-106699","json":"https://secwatch.observer/filing/0001104659-26-106699.json","markdown":"https://secwatch.observer/filing/0001104659-26-106699.md","text":"https://secwatch.observer/filing/0001104659-26-106699.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926106699/0001104659-26-106699-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926106699/tm2624937d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T20:04:20.752890+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}